While GAS6-mediated activation of RON has not yet been reported in breast cancer, its effects on resistance to ADT in a RON-dependent manner in prostate cancer suggests at least some overlapping function of ligand-dependent activation irrespective of whether the ligand is HGFL or GAS6. The gene discussed is MST1; the disease is prostate carcinoma.